A new Institute for Supply Management report says U.S. manufacturing PMI remains below 50 in June, indicating continued contraction in the sector.
Persistent trade policy uncertainty is causing a “tariff mess,” leading to halted sales and deferred capital investments.
Executive sentiment is overwhelmingly negative, with pessimistic views outpacing positive ones by a large margin.
The manufacturing sector faces challenges from weak demand, rising costs, and global economic pressures.
The U.S. manufacturing sector shrank for the fourth consecutive month in June, as weak demand, rising costs, and paralyzing uncertainty over trade policy continue to drag on the industry, according to the latest Institute for Supply Management report.
Flashing red: While the headline index nudged up slightly to 49%, a reading under 50 still signals contraction. The details paint a grim picture: new orders fell for the fifth straight month, and the employment index sank further as companies continue to shed jobs rather than hire.
The view from the floor: A paralyzing anxiety over trade policy is the core problem, with one executive in the machinery sector calling the situation a “tariff mess” that has “utterly stopped sales.” Another manager noted that customers are holding off on large capital purchases until stability returns, softening the sales outlook for the rest of 2025.
Reading the room: The pessimism is palpable, with negative comments from executives outpacing positive ones by a staggering eleven-to-one ratio, a sharp downturn from the five-to-one ratio just a month prior, as noted by Manufacturing Dive. The slump isn’t happening in a vacuum, as China’s factory activity also shrank for a third consecutive month.
The bottom line: With new orders weak and tariff uncertainty looming, the outlook for U.S. factories remains shaky for the rest of the year. But not all economic reports are in agreement, as S&P Global’s competing index painted a more optimistic picture for U.S. manufacturing. Meanwhile, some sectors are feeling specific pain points, with reports of pronounced headwinds in the biopharmaceutical space, including hiring freezes and falling stock prices.
Reading Recap:
